12 Key pharmacokinetic and pharmacodynamic parameters that correlate with the anti-tumor activity of a bispecific PD-L1 conditional 4–1BB agonist

by Quinn Deveraux, Heather Kinkead, Chelsie Macedo, Angelica Sanabria, Garrett Cyprus, Rajay Pandit, James Kalabus, Bryan Becklund, Florian Sulzmaier, John Timmer, Brendan Eckelman, Analeah Heidt
Published 2021-11-01

722 INBRX-121 is an NKp46-targeted detuned IL-2 with antitumor activity as a monotherapy or in combination with multiple cancer immunotherapy modalities

by Heather Kinkead, Chelsie Macedo, Angelica Sanabria, Rajay Pandit, Florian Sulzmaier, John Timmer, Brendan Eckelman, Analeah Heidt, Anya Polovina, Nadja Kern, Abrahim Hussain, Sae Jeong Ahn, William Crago
Published 2021-11-01

INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses

by Jason Ho, Chelsie Macedo, Garrett Cyprus, Rajay Pandit, Anya Polovina, Nadja Kern, Abrahim Hussain, Sae Jeong Ahn, William Crago, Emily Rowell, Florian J Sulzmaier, John C Timmer, Brendan P Eckelman
Published 2023-01-01